Abstract

This Program Grant consisting of four Projects, two scientific Cores and one Administrative Core is focused on testing the role of neutralizing antibodies and cellular immunity induced by infection or elicited by candidate vaccines comprising selected domains of the HIV and SIV envelopes for their ability to protect against virus challenge_. The challenge studies will be conducted In chimps and macaques housed in primate facilities at distant sites, while the virologic, immunologic and molecular studies will be done at Duke University. The major goal of these studies is to determine what role the principal neutralizing determinant (PND) of HIV which is situated within the V3 loop will play in protection against viral infection. Host responses to the PND Involving both the humoral and cellular arms will be determined and approaches to optimize these will be tested and refined. We also hope to uncover to what degree vaccine principles which are relevant to HIV-1 will apply to SIV and vice versa.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA043447-07
Application #
3094033
Study Section
Special Emphasis Panel (SRC (L1))
Project Start
1986-07-01
Project End
1995-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Palker, T J; Muir, A J; Spragion, D E et al. (1996) The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology 224:415-26
Haynes, B F; Pantaleo, G; Fauci, A S (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-8
Haynes, B F; Moody, M A; Heinley, C S et al. (1995) HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. AIDS Res Hum Retroviruses 11:211-21
Toso, J F; Chen, C H; Mohr, J R et al. (1995) Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J Infect Dis 172:964-73
Liao, H X; Lee, D M; Levesque, M C et al. (1995) N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. J Immunol 155:3938-45
Klinman, D M; Haynes, B F; Conover, J (1995) Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides. AIDS Res Hum Retroviruses 11:97-105
Liao, H X; Haynes, B F (1995) Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Rheum Dis Clin North Am 21:715-40
Hart, M K; Palker, T J; Haynes, B F (1995) Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Pharm Biotechnol 6:821-45
Ferrari, G; King, K; Rathbun, K et al. (1995) IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol 101:239-48
Ferrari, G; Place, C A; Ahearne, P M et al. (1994) Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. J Acquir Immune Defic Syndr 7:325-31

Showing the most recent 10 out of 49 publications